AzTrials
AzTrials

Endometrial CancerTRENDNCT04783467

Time Restricted Eating (TRE) Among Endometrial Cancer Patients

A study testing Time Restricted Eating (TRE) Schedule in people with Endometrial Cancer, run by University of Utah at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Endometrial Cancer
What is being tested?
Time Restricted Eating (TRE) Schedule
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteUnited States
Study dates
7 Oct 2021to Jun 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Females aged 18 years or older
  • Diagnosed with endometrial cancer (any stage)
  • Clinically overweight or obese (BMI >= 25 kg/m2)
  • At least 3 months post-cancer surgery and/or treatment
  • Weight stable for 3 months prior to beginning the study (<4kg weight loss/gain)
  • Have a cell phone that is able to download a phone App and able to use phone during the day

Who cannot join

  • Persons with special dietary requirements
  • Unable to provide informed consent
  • Unable to read, write, or fill in questionnaires in English
  • Insulin dependent diabetes
  • Night shift workers
  • Persons not able to use cell phone during day (like for work)

Trial locations and contacts

1 site in 1 country.

Mary Playdon, PhD, MPH contact

(801) 213-6264

mary.playdon@hci.utah.edu

United States1 site, 1 recruiting
  • Huntsman Cancer Institute

    Salt Lake City, Utah, 84112

    Mary Playdon, PhD, MPH, 801-213-6264, mary.playdon@hci.utah.edu

    Recruiting

Other trials in United States

About this study

Official title: Feasibility and Acceptability of Time Restricted Eating (TRE) Among Endometrial Cancer Patients: the TREND Study

The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic health in this population.

Read the detailed description

Enrollment: The study team will aim to recruit 15 endometrial cancer patients seen at the Huntsman Cancer Hospital Clinics. Consent may be completed via phone/email or in-person with the study clinical coordinator.

Dietary Intervention: Participants who are consented into the study will participate in a 16-week randomized dietary crossover intervention. The dietary intervention includes 5 study visits, and features a baseline visit, 2-week run-in period, 4-week control diet schedule with prepared frozen meals provided to participants, 4-week washout period, and a 6-week, 8 to 10-hour Time Restricted Eating (TRE) protocol (meal provision with 8 to 10-hour eating and 14 to 16-hour fasting periods). Women will be randomized to either control or TRE, then crossover to the other condition. For the control schedule, women will receive frozen lunch and dinner meals and be provided with a standardized breakfast and snacks menu, and there are no restrictions on timing of eating. For the TRE schedule, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. Fasting period will ramp up during the first week (e.g., Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the eating period at the same time each day.

Study Visits and Assessments: Women will attend in-person study visits at the Huntsman Cancer Institute Center for Health Outcomes and Population Equity (HOPE).

  • Baseline Visit (Visit 1): The clinical coordinator will obtain consent from the participant. Once consented, women will complete questionnaires to capture information on clinical and demographic factors, and chronotype. Height will be measured using stadiometer, weight will be measured using calibrated scales, waist circumference with measuring tape and blood pressure (BP) using an electronic BP monitor. Participants may take home questionnaires, with mailer, to complete at home.
  • 2-Week Run-In Period: The purpose of the run-in period is to record women's usual times of eating episodes and appetite while following their habitual diet. Appetite will be measured using the MyCircacianClock (mCC) phone app that has the capability to sample subjects' current behaviors and experiences in real time in their natural environment. Women will complete 3 x 24-hour dietary recalls on non-consecutive days (ASA-24) and a physical activity recall (ACT24 available online or phone app, or via telephone conference with the clinical coordinator). Sleep and activity will also be objectively measured for 7-days using an Actiwatch.
  • Visit 2: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured.
  • Control OR TRE Schedules: The participants will be expected to follow their randomized schedule for meal timing. During these schedules, for both study groups, participants will record timing of eating episodes daily using the MyCircadianClock app, complete 3 x 24-hour recalls (ASA24), 1 x ACT24 activity recall, and 7-days of sleep/physical activity will be objectively measured via Actiwatch.
  • Visit 3: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured.
  • 4-Week Washout Period: During the washout period, women can return to their usual lifestyle. Meals will not be provided during this time.
  • Visit 4: Visit 4 will include a telephone call only to discuss the next study phase and schedule meal provision.
  • Visit 5: Women will provide fasting blood and stool samples. Weight, waist circumference and blood pressure will be measured. An exit interview may occur in person or via phone/video conference to ask questions about how well the intervention was tolerated and allow participants to provide feedback.
  • Follow-Up: Approximately 6-months after consent and roughly 10 weeks after the end of the dietary intervention, participants will be asked to complete a follow-up questionnaire.
Being tested
Time Restricted Eating (TRE) Schedule
Medical subject headings
Endometrial Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Time Restricted Eating (TRE) ScheduleBehavioural

    [See arm/group descriptions]

Study groups in NCT04783467
Study groupRoleWhat they receive
Time Restricted Eating (TRE) ScheduleExperimentalFor 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.
Receives: Behavioral: Time Restricted Eating (TRE) Schedule
Control ScheduleNo interventionFor 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Women Referred that are Consented

    Feasibility of the TRE intervention will be measured be calculating the proportion (%) of women who were referred that were consented into the study. The study will be considered feasible of > 70% of participants are consented and retained.

    Measured: From baseline to Visit 5 (Week 16)

  2. Attrition as a Function of Time

    Number of participants who withdraw throughout the course of the study.

    Measured: From baseline to Visit 5 (Week 16)

  3. Percent of Scheduled Assessments Completed

    Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.

    Measured: From baseline to Visit 5 (Week 16)

  4. Number of TRE-Adherent Days per Week

    Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-16 hours per day during the TRE phase according to the MCC App mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.

    Measured: From baseline to Visit 5 (Week 16)

  5. Fidelity of Time Restricted Eating (TRE) Intervention

    Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%

    Measured: From baseline to Visit 5 (Week 16)

Secondary outcomes (9)
  1. Change in blood pressure assessed via electronic blood pressure monitor

    Blood pressure will be taken using an electronic blood pressure monitor.

    Measured: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  2. Change in waist circumference assessed via measuring tape

    Waist circumference will be measured using a measuring tape.

    Measured: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  3. Change in BMI assessed via height and weight

    Participants' height and weight will be measured with stadiometer and electronic scales and used to calculate BMI.

    Measured: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  4. Change in fasting blood glucose assessed via blood draw

    A small sample of blood will be taken from participants at designated study visits.

    Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  5. Change in HOMA-IR assessed via blood draw

    A small sample of blood will be taken from participants at designated study visits.

    Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  6. Change in c-peptide assessed via blood draw

    A small sample of blood will be taken from participants at designated study visits

    Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  7. Change in triglycerides assessed via blood draw

    A small sample of blood will be taken from participants at designated study visits

    Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  8. Change in HDL-cholesterol assessed via blood draw

    A small sample of blood will be taken from participants at designated study visits

    Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

  9. Change in high sensitivity C-reactive protein assessed via blood draw

    A small sample of blood will be taken from participants at designated study visits

    Measured: Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2021
  2. Study start7 Oct 2021
  3. Primary completionJun 2024 (estimated)
  4. Study completionJun 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04783467
Sponsor's protocol ID
IRB_00126714
Acronym
TREND
Status last verified
Nov 2023
First submitted
18 Feb 2021
Last updated
30 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Agnew H, Kitson S, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.

    PubMed 36971688

Questions about this trial

What is this clinical trial studying?

A study testing Time Restricted Eating (TRE) Schedule in people with Endometrial Cancer, run by University of Utah at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mary Playdon, PhD, MPH ((801) 213-6264, mary.playdon@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Women Referred that are Consented (time frame: From baseline to Visit 5 (Week 16)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04783467, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in